The researchers published another study in which they designed a qPCR-based test (ExoDx EGFR) capable of interrogating a panel of 29 mutations in the EGFR gene, which included the activating and resistance mutations utilizing exosomal RNA/DNA and cfDNA obtained from the plasma of a cohort consisting of 110 NSCLC patients According to the assay’s performance results, its general sensitivity was 90% for L858R, 83% for T790M, and 73% for exon 19 deletion with corresponding specificities of 100%, 100%, and 96%, respectively [122]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.